Drug Profile
Hepatitis B immune globulin - ADMA Biologics/Nabi Biopharmaceuticals
Alternative Names: HBVIg - Biotetst Pharmaceuticals; HBVIg - Nabi Biopharmaceuticals; HEBIG; Hepatitis B immune globulin-human - Biotest Pharmaceuticals; Human hepatitis B immunoglobulin - Biotest Pharmaceuticals; NABI-HB; Nabi-HBLatest Information Update: 15 Feb 2023
Price :
$50
*
At a glance
- Originator Nabi Biopharmaceuticals
- Developer ADMA Biologics
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 15 Feb 2023 9380723; NO UPDATE; Patent information is already covered
- 05 Mar 2021 Launched for Hepatitis B (Prevention) in South Korea (IM)
- 03 Mar 2021 ADMA Biologic has patent protection for the compositions and methods of manufacturing, and methods of using the human plasma immunoglobulin for the treatment of immunodeficiency in USA and Europe